United States Ninth Circuit

In a suit against a brand-name and a generic drug manufacturer alleging restraint-of-trade and monopolization of the market for a blood pressure medication, judgment for defendants is affirmed in part over plaintiff's evidentiary challenges, but reversed in part where plaintiff produced sufficient evidence to go to trial on its claim that defendant had violated the Sherman Act by enforcing a patent obtained through fraud.

Appellate Information

• Argued 02/04/2008
• Decided 01/13/2009
• Published 01/13/2009

Judges

• WILLIAM A. FLETCHER, Circuit Judge:, Before:  ALEX KOZINSKI, Chief Judge, DIARMUID F. O'SCANNLAIN, and W. FLETCHER, Circuit Judges.

Court

• United States Ninth Circuit

Counsel

• For Appellant:
  
• David C. Frederick, Kellogg Huber Hansen Todd & Evans, WA, D.C., W. Scott Simmer, Hardy Vieux, Robins, Kaplan, Miller & Ciresi, Minneapolis, MN, for the appellant.


• For Appellees:
  
• Paul Olszowka, Wildman, Harrold, Allen & Dixon, Chicago, IL, Rohit K. Singla, Munger Tolles & Olson, San Francisco, CA, Stuart Neil Senator, Jeffrey I. Weinberger, Munger Tolles & Olson, Los Angeles, CA, Bryan Alexander Merryman, White & Case, Los Angeles, CA Robert A. Milne, White & Case, New York, NY, for the appellees.